Last checked at 
LONDON (Alliance News) - Life sciences company ValiRx PLC on Thursday said the UK Patent Office has given its approval for a further indication for the VAL201 compound.
The new patent covers a further indication for the compound in endometriosis or hormone-induced abnormal cell growth in women.
Based on results in endometrial models, VAL201 has been shown to reduce abnormal endometrial growth, whilst leaving other hormone-induced activities working normally, ValiRx said.
"The granting of this latest patent not only further extends our global geographic patent coverage, but it also complements our announcement earlier this week on the successful first results from our lead compound, VAL201 in its Phase I/II clinical trial," said ValiRx Chief Executive Satu Vainikka.
Shares in ValiRx were trading up 2.3% at 0.225 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
